The other essential point is the implication of CXCL1-CXCR2 signaling-mediated neutrophil suppression in allergic airway inflammation that should be further investigated during the development of CXCR1/CXCR2 inhibition therapy for asthma treatment [47,48]. The gene discussed is CXCR2; the disease is asthma.